Cargando…
Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial
Background: Hemorrhagic transformation (HT) is an important complication of intravenous thrombolysis with alteplase. HT can show a wide range from petechiae to parenchymal hematoma with mass effect with varying clinical impact. We studied clinical and imaging characteristics of patients with HT and...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483750/ https://www.ncbi.nlm.nih.gov/pubmed/32982951 http://dx.doi.org/10.3389/fneur.2020.00957 |
_version_ | 1783580958963793920 |
---|---|
author | Jensen, Märit Schlemm, Eckhard Cheng, Bastian Lettow, Iris Quandt, Fanny Boutitie, Florent Ebinger, Martin Endres, Matthias Fiebach, Jochen B. Fiehler, Jens Galinovic, Ivana Thijs, Vincent Lemmens, Robin Muir, Keith W. Nighoghossian, Norbert Pedraza, Salvador Simonsen, Claus Z. Gerloff, Christian Thomalla, Götz |
author_facet | Jensen, Märit Schlemm, Eckhard Cheng, Bastian Lettow, Iris Quandt, Fanny Boutitie, Florent Ebinger, Martin Endres, Matthias Fiebach, Jochen B. Fiehler, Jens Galinovic, Ivana Thijs, Vincent Lemmens, Robin Muir, Keith W. Nighoghossian, Norbert Pedraza, Salvador Simonsen, Claus Z. Gerloff, Christian Thomalla, Götz |
author_sort | Jensen, Märit |
collection | PubMed |
description | Background: Hemorrhagic transformation (HT) is an important complication of intravenous thrombolysis with alteplase. HT can show a wide range from petechiae to parenchymal hematoma with mass effect with varying clinical impact. We studied clinical and imaging characteristics of patients with HT and evaluated whether different types of HT are associated with functional outcome. Methods: We performed a post-hoc analysis of WAKE-UP, a multicenter, randomized, placebo-controlled trial of MRI-guided intravenous alteplase in unknown onset stroke. HT was assessed on follow-up MRI or CT and diagnosed as hemorrhagic infarction type 1 and type 2 (HI1 and HI2, combined as HI), and parenchymal hemorrhage type 1 and type 2 (PH1 and PH2, combined as PH). Severity of stroke symptoms was assessed using the National Institutes of Health Stroke Scale (NIHSS) at baseline. Stroke lesion volume was measured on baseline diffusion weighted imaging (DWI). Primary endpoint was a favorable outcome defined as a modified Rankin Scale score 0–1 at 90 days. Results: Of 483 patients included in the analysis, 95 (19.7%) showed HI and 21 (4.4%) had PH. Multiple logistic regression analysis identified treatment with alteplase (OR, 2.08 [95% CI, 1.28–3.40]), baseline NIHSS score (OR, 1.11 [95% CI, 1.05–1.17]), DWI lesion volume (OR, 1.03 [95% CI, 1.01–1.05]), baseline glucose levels (OR, 1.01 [95% CI, 1.00–1.01]) and atrial fibrillation (OR, 3.02 [95% CI, 1.57–5.80]) as predictors of any HT. The same parameters predicted HI. Predictors of PH were baseline NIHSS score (OR, 1.11 [95% CI, 1.01–1.22]) and as a trend treatment with alteplase (OR, 2.40 [95% CI, 0.93–6.96]). PH was associated with lower odds of favorable outcome (OR 0.25, 95% [CI 0.05–0.86]), while HI was not. Conclusion: Our results indicate that HI is associated with stroke severity, cardiovascular risk factors and thrombolysis. PH is a rare complication, more frequent in severe stroke and with thrombolysis. In contrast to HI, PH is associated with worse functional outcome. The impact of HT after MRI-guided intravenous alteplase for unknown onset stroke on clinical outcome is similar as in the trials of stroke thrombolysis within a known early time-window. |
format | Online Article Text |
id | pubmed-7483750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74837502020-09-25 Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial Jensen, Märit Schlemm, Eckhard Cheng, Bastian Lettow, Iris Quandt, Fanny Boutitie, Florent Ebinger, Martin Endres, Matthias Fiebach, Jochen B. Fiehler, Jens Galinovic, Ivana Thijs, Vincent Lemmens, Robin Muir, Keith W. Nighoghossian, Norbert Pedraza, Salvador Simonsen, Claus Z. Gerloff, Christian Thomalla, Götz Front Neurol Neurology Background: Hemorrhagic transformation (HT) is an important complication of intravenous thrombolysis with alteplase. HT can show a wide range from petechiae to parenchymal hematoma with mass effect with varying clinical impact. We studied clinical and imaging characteristics of patients with HT and evaluated whether different types of HT are associated with functional outcome. Methods: We performed a post-hoc analysis of WAKE-UP, a multicenter, randomized, placebo-controlled trial of MRI-guided intravenous alteplase in unknown onset stroke. HT was assessed on follow-up MRI or CT and diagnosed as hemorrhagic infarction type 1 and type 2 (HI1 and HI2, combined as HI), and parenchymal hemorrhage type 1 and type 2 (PH1 and PH2, combined as PH). Severity of stroke symptoms was assessed using the National Institutes of Health Stroke Scale (NIHSS) at baseline. Stroke lesion volume was measured on baseline diffusion weighted imaging (DWI). Primary endpoint was a favorable outcome defined as a modified Rankin Scale score 0–1 at 90 days. Results: Of 483 patients included in the analysis, 95 (19.7%) showed HI and 21 (4.4%) had PH. Multiple logistic regression analysis identified treatment with alteplase (OR, 2.08 [95% CI, 1.28–3.40]), baseline NIHSS score (OR, 1.11 [95% CI, 1.05–1.17]), DWI lesion volume (OR, 1.03 [95% CI, 1.01–1.05]), baseline glucose levels (OR, 1.01 [95% CI, 1.00–1.01]) and atrial fibrillation (OR, 3.02 [95% CI, 1.57–5.80]) as predictors of any HT. The same parameters predicted HI. Predictors of PH were baseline NIHSS score (OR, 1.11 [95% CI, 1.01–1.22]) and as a trend treatment with alteplase (OR, 2.40 [95% CI, 0.93–6.96]). PH was associated with lower odds of favorable outcome (OR 0.25, 95% [CI 0.05–0.86]), while HI was not. Conclusion: Our results indicate that HI is associated with stroke severity, cardiovascular risk factors and thrombolysis. PH is a rare complication, more frequent in severe stroke and with thrombolysis. In contrast to HI, PH is associated with worse functional outcome. The impact of HT after MRI-guided intravenous alteplase for unknown onset stroke on clinical outcome is similar as in the trials of stroke thrombolysis within a known early time-window. Frontiers Media S.A. 2020-08-28 /pmc/articles/PMC7483750/ /pubmed/32982951 http://dx.doi.org/10.3389/fneur.2020.00957 Text en Copyright © 2020 Jensen, Schlemm, Cheng, Lettow, Quandt, Boutitie, Ebinger, Endres, Fiebach, Fiehler, Galinovic, Thijs, Lemmens, Muir, Nighoghossian, Pedraza, Simonsen, Gerloff and Thomalla. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Jensen, Märit Schlemm, Eckhard Cheng, Bastian Lettow, Iris Quandt, Fanny Boutitie, Florent Ebinger, Martin Endres, Matthias Fiebach, Jochen B. Fiehler, Jens Galinovic, Ivana Thijs, Vincent Lemmens, Robin Muir, Keith W. Nighoghossian, Norbert Pedraza, Salvador Simonsen, Claus Z. Gerloff, Christian Thomalla, Götz Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial |
title | Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial |
title_full | Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial |
title_fullStr | Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial |
title_full_unstemmed | Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial |
title_short | Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial |
title_sort | clinical characteristics and outcome of patients with hemorrhagic transformation after intravenous thrombolysis in the wake-up trial |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483750/ https://www.ncbi.nlm.nih.gov/pubmed/32982951 http://dx.doi.org/10.3389/fneur.2020.00957 |
work_keys_str_mv | AT jensenmarit clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT schlemmeckhard clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT chengbastian clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT lettowiris clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT quandtfanny clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT boutitieflorent clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT ebingermartin clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT endresmatthias clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT fiebachjochenb clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT fiehlerjens clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT galinovicivana clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT thijsvincent clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT lemmensrobin clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT muirkeithw clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT nighoghossiannorbert clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT pedrazasalvador clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT simonsenclausz clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT gerloffchristian clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial AT thomallagotz clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial |